-- 據奧本海默週一發布的報告稱，Whitehawk Therapeutics (WHWK) 公佈了其早期抗體藥物偶聯物 (ADC) 的「可靠」臨床前數據集，表明其對實體瘤靶點的潛在療效具有「顯著的臨床證據」。 報告指出，該公司的 ADC 產品組合中，HWK-007 和 HWK-016 目前正在進行臨床研究，HWK-206 預計將在第三季啟動。 奧本海默表示，靶向蛋白酪氨酸激酶 7 (PTK7) 的 HWK-007 顯示出“強效活性”，而 HWK-016 則顯示出比之前靶向粘蛋白 16 (MUC16) 的 ADC 更優的療效。該公司還補充道，HWK-206 也顯示出對癲癇相關同源蛋白 6 (SEZ6) 的增強療效。 奧本海默公司給予 Whitehawk Therapeutics 「跑贏大盤」評級，目標價為 5 美元。
Price: $4.21, Change: $-0.02, Percent Change: -0.47%
South Korean shares closed at a new high on Monday, with the primary index crossing the 6,600 level amid a rally led by chip stocks and power equipment manufacturers.The Korea Composite Stock Price Index or Kospi rose 139.4 points, or 2.2%, to end at 6,615.03. The Kosdaq also increased by 22.34 points, or 1.9%, to close at 1,226.18.Shares of chipmakers such as Samsung Electronics (KRX:005930) and SK Hynix (KRX:000660) added over 2% and nearly 6% at market close, while those of Kosdaq-listed Fadu (KOSDAQ:440110) jumped over 19%.Gains were also driven by shares of power equipment manufacturers LS Electric (KRX:010120) and Hyosung Heavy Industries (KRX:298040), which added nearly 13% and 11%, respectively.In corporate news, Fadu posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.
UCO Bank (NSE:UCOBANK, BOM:532505) net profit rose to 8.01 billion Indian rupees in the fiscal fourth quarter from 6.52 billion rupees a year ago, according to a Saturday filing to the Indian stock exchanges.Earnings per share during the quarter ended March 31 climbed to 0.64 rupees from 0.56 rupees last year.Interest earned by the lender in fiscal Q4, however, slipped to 66.6 billion rupees from 67.4 billion rupees a year earlier.The bank's board also recommended a dividend of 0.44 rupees per share for the financial year 2025-26.
Prudential (SGX:K6S, HKG:2378) bought back 287,211 shares in London on April 24 at an average price of about 11.20 pounds sterling apiece, according to a Monday Hong Kong bourse filing.The insurer intends to cancel the repurchased shares.Following the transaction, the company will have about 2.52 billion shares in issue.